DocGo narrows full-year 2026 revenue guidance to $305-$310 mln, excluding Hicuity Health acquisition
Company lowers 2026 adjusted EBITDA outlook to ($17)-($22) mln from prior ($5)-($10) mln
DocGo expects to exit 2026 at a profitable adjusted EBITDA run rate
Overview
US mobile health and medical transport provider's Q2 revenue declined, missing analyst expectations
Company signed definitive deal to acquire virtual care provider Hicuity Health
Result drivers and operating trends
MIGRANT PROGRAM WIND-DOWN - Co said Q2 revenue decline was entirely due to wind-down of migrant-related programs, which generated zero revenue in Q2 2026 compared to $18.8 mln in Q2 2025
CORE BUSINESS GROWTH - Excluding migrant-related programs, revenue increased 19% year over year, driven by organic growth and SteadyMD contributions
RECORD VOLUMES - Co achieved record volumes across all major business lines, including US medical transportation, healthcare in the home, mobile phlebotomy, cardiac and remote patient monitoring, and virtual care & lab orders
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy"
Wall Street's median 12-month price target for DocGo Inc. is $1.75, about 162.2% above its August 14 closing price of $0.67
DCGO•
